Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials

What Was Tested

This randomized controlled trial paper looks at Relaxin (Serelaxin) in the context of skin sensitivity and body aches on glp-1 medicines.

The modified Rodnan skin score (MRSS) is a standard outcome measure for skin disease in SSc and calculated by summation of skin thickness in 17 different body sites (total score = 51).

Their objective was to evaluate the sensitivity of change over time of individual body sites used in the calculation of total MRSS.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The participants were allocated by chance, so the Relaxin (Serelaxin) group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Relaxin (Serelaxin) could be set against what happens without it.

The researchers analysed two randomized placebo controlled clinical trials investigating the effect of either recombinant human relaxin or type I oral collagen in dcSSc.

Both trials used MRSS as the primary outcome measure.

The researchers calculated the mean change and the effect size (ES) for each individual body site used in the total MRSS for each study.

Magnitude of ES was assessed using Cohen's rule of thumb for ES.

What Was Measured

PubMed files the paper under topics including Collagen Type I, Recombinant Proteins, Relaxin, Scleroderma, Diffuse, Sensitivity and Specificity and Skin.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Relaxin (Serelaxin) in people with skin sensitivity and body aches on glp-1 medicines.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (Rheumatology (Oxford, England)), a journal based in England.

More context: the Relaxin (Serelaxin) compound page, Skin sensitivity and body aches on GLP-1 medicines research.